Developing scalable cell replacement therapies for the world

Eyestem is a cell therapy company founded by a top-class management team consisting of clinical trial, cell therapy and ophthalmology experts. It also boasts a world class advisory board and has built collaborations with pioneers and leaders in the space. Our long-term vision is to create a scalable cell therapy platform to treat incurable diseases and democratize access to these newer technologies for the bottom 99 % of the population globally.

We have embedded manufacturing and quality processes in the platform which will enable us to create a virtuous cycle of innovation and decrease the time to market for such therapies. Our lead product out of the platform is EyecyteRPE aimed at treating Dry AMD (Age-related Macular Degeneration). Dry AMD is the largest cause of incurable blindness in people above 60 and affects roughly 170 million people worldwide. Pivotal efficacy and safety studies for this product have started at Oregon Health and Science University and we expect to begin first in man studies for the same in 2022.

Enroll in our Global Research Alliance

Recent Scientific Papers

Surendran H, Nandakumar S, Konala…

Transplantation of retinal pigment epithelium and photoreceptors generated concomitantly via small molecule-mediated differentiation rescues visual function in rodent models of retinal degeneration

 Stem Cell Res Ther. 2021; 12: 70. doi: 10.1186/s13287-021-02134-x

Surendran H, Nandakumar S, Pal…

Human Induced Pluripotent Stem Cell-Derived Lung Epithelial System for SARS-CoV-2 Infection Modeling and Its Potential in Drug Repurposing

 Stem Cells Dev . 2020 Sep 18. doi: 10.1089/scd.2020.0152

Pal R, Surendran H, Nandakumar…

Transplantation of retinal pigment epithelium (RPE) and photoreceptor progenitors (PRP) generated through a xeno-free unified protocol showed improved visual sensitivity in two rodent models

 Investigative Ophthalmology & Visual Science June 2020, Vol.61, 2290.

Konala VBR, Nandakumar S, Battu…

Derivation of three induced pluripotent stem cell lines under feeder-free culture conditions from peripheral blood mononuclear cells (PBMC) of Indian patients suffering from inherited retinal diseases carrying different mutations

 Stem Cell Res . 2020 May;45:101757. doi: 10.1016/j.scr.2020.101757.

Battu R, Mallipatna A, Elackatt NJ, Schouten JSAG,

Webers Challenges of managing retinal dystrophies: an experience from south India. Ophthalmic Genetics.

2018. 39(1): 1-3.

Surendran H, Rathod RR. Pal R.

Generation of transplantable Retinal Pigmented Epithelial (RPE) cells for treatment of Age-related Macular Degeneration (AMD

2018. Meth Mol Biol. (Accepted).

Battu R, Mohan A, Khanna A, Kumar A, Shetty R

Retinal oxygen saturation in Retinitis Pigmentosa and macular dystrophies in Asian Indian eyes. Invest Ophthalmol Vis Sci. 2015.

56(5): 2798-802.

Battu R, Khanna A, Hegde B, Berendschot TT, Grover G, Schouten JS.

Correlation of Structure and Function of the Macula in patients with Retinitis Pigmentosa. Eye (Lond).

2015. 29(7): 895-901.
View all Scientific Papers

EyestemFollow

Eyestem
Eyestem@EyestemResearch·
12 Oct

Delighted to announce an exciting publication on interventional strategies to treat Parkinson's disease with intranasal administration of Neural Precursor Cells. Huge thanks to the @IndraniDatta12 lab at NIMHANS for the collaboration
https://www.linkedin.com/posts/eyestem-research_interventional-strategies-for-parkinson-disease-activity-6853561385180389377-7Kmh

Twitter 1447798783165620225
Eyestem@EyestemResearch·
24 Sep

Hear our Founder and CEO speak at the upcoming 2nd International Cell and Gene therapy Summit in Shanghai on democratizing access to cell therapy.

Twitter 1441298600651149314

Career Openings

Research Associate

Project: Hands-on experience in gene editing tools like ZFN, TALEN, CRISPR/Cas9 preferred

Junior / Senior Research Fellow

Project: Hands-on experience in mammalian cell and tissue culture (preferably with stem or progenitor cells) and basic cell biology techniques

View all